An endocannabinoid that contains linoleate in place of the arachidonate moiety of AEA; has been detected in porcine brain and murine peritoneal macrophages and has weak affinity for the CB1 and CB2 receptors (Kis =10 µM and 25 µM, respectively); 4-fold less potent than AEA at causing catalepsy in mice (ED50 = 26.5 mg/kg); increases ERK phosphorylation and AP-1-dependent transcription approximately 1.5 fold at 15 µM in a CB-receptor-independent manner; inhibits human FAAH-dependent hydrolysis of AEA (Ki = 9.0 µM), but is also effectively hydrolyzed by the enzyme.